<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39273473</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Nicotinamide Mononucleotide: Research Process in Cardiovascular Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9526</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25179526</ELocationID><Abstract><AbstractText>Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) is an essential metabolite that plays a crucial role in diverse biological processes, including energy metabolism, gene expression, DNA repair, and mitochondrial function. An aberrant NAD<sup>+</sup> level mediates the development of cardiovascular dysfunction and diseases. Both in vivo and in vitro studies have demonstrated that nicotinamide mononucleotide (NMN), as a NAD<sup>+</sup> precursor, alleviates the development of cardiovascular diseases such as heart failure, atherosclerosis, and myocardial ischemia/reperfusion injury. Importantly, NMN has suggested pharmacological activities mostly through its involvement in NAD<sup>+</sup> biosynthesis. Several clinical studies have been conducted to investigate the efficacy and safety of NMN supplementation, indicating its potential role in cardiovascular protection without significant adverse effects. In this review, we systematically summarize the impact of NMN as a nutraceutical and potential therapeutic drug on cardiovascular diseases and emphasize the correlation between NMN supplementation and cardiovascular protection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Haoyuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nutrition and Food Hygiene, School of Public Health, Dalian Medical University, Dalian 116044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Ding</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Public Health, Dalian Medical University, Dalian 116044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Health Toxicology, School of Public Health, Dalian Medical University, Dalian 116044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Public Health, Dalian Medical University, Dalian 116044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ningning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Nutrition and Food Hygiene, School of Public Health, Dalian Medical University, Dalian 116044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Nutrition and Food Hygiene, School of Public Health, Dalian Medical University, Dalian 116044, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Guang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Nutrition and Food Hygiene, School of Public Health, Dalian Medical University, Dalian 116044, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1094-61-7</RegistryNumber><NameOfSubstance UI="D009537">Nicotinamide Mononucleotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0U46U6E8UK</RegistryNumber><NameOfSubstance UI="D009243">NAD</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009537" MajorTopicYN="Y">Nicotinamide Mononucleotide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009243" MajorTopicYN="N">NAD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NAD+</Keyword><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">nicotinamide mononucleotide</Keyword><Keyword MajorTopicYN="N">nicotinamide mononucleotide supplementation</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39273473</ArticleId><ArticleId IdType="pmc">PMC11394709</ArticleId><ArticleId IdType="doi">10.3390/ijms25179526</ArticleId><ArticleId IdType="pii">ijms25179526</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xie N., Zhang L., Gao W., Huang C., Huber P.E., Zhou X., Li C., Shen G., Zou B. NAD+ metabolism: Pathophysiologic mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 2020;5:227. doi: 10.1038/s41392-020-00311-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00311-7</ArticleId><ArticleId IdType="pmc">PMC7539288</ArticleId><ArticleId IdType="pubmed">33028824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W., Mo F., Zhang Z., Huang M., Wei X. Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD+ Metabolism. Front. Cell Dev. Biol. 2020;8:246. doi: 10.3389/fcell.2020.00246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00246</ArticleId><ArticleId IdType="pmc">PMC7198709</ArticleId><ArticleId IdType="pubmed">32411700</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Hu X., Li J., Liu J., Baks-Te Bulte L., Wiersma M., Malik N.U., van Marion D.M.S., Tolouee M., Hoogstra-Berends F., et al. DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD+ depletion in experimental atrial fibrillation. Nat. Commun. 2019;10:1307. doi: 10.1038/s41467-019-09014-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09014-2</ArticleId><ArticleId IdType="pmc">PMC6428932</ArticleId><ArticleId IdType="pubmed">30898999</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Li H., Tien C.L., Jain M.K., Zhang L. Kruppel-Like Factor 15 Regulates the Circadian Susceptibility to Ischemia Reperfusion Injury in the Heart. Circulation. 2020;141:1427–1429. doi: 10.1161/CIRCULATIONAHA.119.041664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.041664</ArticleId><ArticleId IdType="pmc">PMC7197441</ArticleId><ArticleId IdType="pubmed">32339045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R., Shen Y., Zhou L., Sangwung P., Fujioka H., Zhang L., Liao X. Short-term administration of Nicotinamide Mononucleotide preserves cardiac mitochondrial homeostasis and prevents heart failure. J. Mol. Cell. Cardiol. 2017;112:64–73. doi: 10.1016/j.yjmcc.2017.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2017.09.001</ArticleId><ArticleId IdType="pmc">PMC6257991</ArticleId><ArticleId IdType="pubmed">28882480</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieganowski P., Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117:495–502. doi: 10.1016/S0092-8674(04)00416-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00416-7</ArticleId><ArticleId IdType="pubmed">15137942</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills K.F., Yoshida S., Stein L.R., Grozio A., Kubota S., Sasaki Y., Redpath P., Migaud M.E., Apte R.S., Uchida K., et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016;24:795–806. doi: 10.1016/j.cmet.2016.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.09.013</ArticleId><ArticleId IdType="pmc">PMC5668137</ArticleId><ArticleId IdType="pubmed">28068222</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino J., Baur J.A., Imai S.I. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27:513–528. doi: 10.1016/j.cmet.2017.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2017.11.002</ArticleId><ArticleId IdType="pmc">PMC5842119</ArticleId><ArticleId IdType="pubmed">29249689</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger F., Lau C., Dahlmann M., Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J. Biol. Chem. 2005;280:36334–36341. doi: 10.1074/jbc.M508660200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508660200</ArticleId><ArticleId IdType="pubmed">16118205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T., Byun J., Zhai P., Ikeda Y., Oka S., Sadoshima J. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS ONE. 2014;9:e98972. doi: 10.1371/journal.pone.0098972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098972</ArticleId><ArticleId IdType="pmc">PMC4048236</ArticleId><ArticleId IdType="pubmed">24905194</ArticleId></ArticleIdList></Reference><Reference><Citation>Long A.N., Owens K., Schlappal A.E., Kristian T., Fishman P.S., Schuh R.A. Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model. BMC Neurol. 2015;15:19. doi: 10.1186/s12883-015-0272-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-015-0272-x</ArticleId><ArticleId IdType="pmc">PMC4358858</ArticleId><ArticleId IdType="pubmed">25884176</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino J., Mills K.F., Yoon M.J., Imai S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14:528–536. doi: 10.1016/j.cmet.2011.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.08.014</ArticleId><ArticleId IdType="pmc">PMC3204926</ArticleId><ArticleId IdType="pubmed">21982712</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogan K.L., Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 2008;28:115–130. doi: 10.1146/annurev.nutr.28.061807.155443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.nutr.28.061807.155443</ArticleId><ArticleId IdType="pubmed">18429699</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardell S.J., Hopf M., Khan A., Dispagna M., Hampton Sessions E., Falter R., Kapoor N., Brooks J., Culver J., Petucci C., et al. Boosting NAD+ with a small molecule that activates NAMPT. Nat. Commun. 2019;10:3241. doi: 10.1038/s41467-019-11078-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-11078-z</ArticleId><ArticleId IdType="pmc">PMC6642140</ArticleId><ArticleId IdType="pubmed">31324777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambronne X.A., Kraus W.L. Location, Location, Location: Compartmentalization of NAD+ Synthesis and Functions in Mammalian Cells. Trends Biochem. Sci. 2020;45:858–873. doi: 10.1016/j.tibs.2020.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2020.05.010</ArticleId><ArticleId IdType="pmc">PMC7502477</ArticleId><ArticleId IdType="pubmed">32595066</ArticleId></ArticleIdList></Reference><Reference><Citation>Okabe K., Yaku K., Tobe K., Nakagawa T. Implications of altered NAD metabolism in metabolic disorders. J. Biomed. Sci. 2019;26:34. doi: 10.1186/s12929-019-0527-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0527-8</ArticleId><ArticleId IdType="pmc">PMC6511662</ArticleId><ArticleId IdType="pubmed">31078136</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateuszuk Ł., Campagna R., Kutryb-Zając B., Kuś K., Słominska E.M., Smolenski R.T., Chlopicki S. Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside. Biochem. Pharmacol. 2020;178:114019. doi: 10.1016/j.bcp.2020.114019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2020.114019</ArticleId><ArticleId IdType="pubmed">32389638</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratajczak J., Joffraud M., Trammell S.A., Ras R., Canela N., Boutant M., Kulkarni S.S., Rodrigues M., Redpath P., Migaud M.E., et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat. Commun. 2016;7:13103. doi: 10.1038/ncomms13103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms13103</ArticleId><ArticleId IdType="pmc">PMC5476803</ArticleId><ArticleId IdType="pubmed">27725675</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannous C., Deloux R., Karoui A., Mougenot N., Burkin D., Blanc J., Coletti D., Lavery G., Li Z., Mericskay M. NMRK2 Gene Is Upregulated in Dilated Cardiomyopathy and Required for Cardiac Function and NAD Levels during Aging. Int. J. Mol. Sci. 2021;22:3534. doi: 10.3390/ijms22073534.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073534</ArticleId><ArticleId IdType="pmc">PMC8036583</ArticleId><ArticleId IdType="pubmed">33805532</ArticleId></ArticleIdList></Reference><Reference><Citation>Grozio A., Mills K.F., Yoshino J., Bruzzone S., Sociali G., Tokizane K., Lei H.C., Cunningham R., Sasaki Y., Migaud M.E., et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat. Metab. 2019;1:47–57. doi: 10.1038/s42255-018-0009-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-018-0009-4</ArticleId><ArticleId IdType="pmc">PMC6530925</ArticleId><ArticleId IdType="pubmed">31131364</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsubota K. The first human clinical study for NMN has started in Japan. NPJ Aging Mech. Dis. 2016;2:16021. doi: 10.1038/npjamd.2016.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npjamd.2016.21</ArticleId><ArticleId IdType="pmc">PMC5515004</ArticleId><ArticleId IdType="pubmed">28721273</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittelli M., Felici R., Pitozzi V., Giovannelli L., Bigagli E., Cialdai F., Romano G., Moroni F., Chiarugi A. Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol. Pharmacol. 2011;80:1136–1146. doi: 10.1124/mol.111.073916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.111.073916</ArticleId><ArticleId IdType="pubmed">21917911</ArticleId></ArticleIdList></Reference><Reference><Citation>Soma M., Lalam S.K. The role of nicotinamide mononucleotide (NMN) in anti-aging, longevity, and its potential for treating chronic conditions. Mol. Biol. Rep. 2022;49:9737–9748. doi: 10.1007/s11033-022-07459-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-022-07459-1</ArticleId><ArticleId IdType="pubmed">35441939</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanada S., Komuro I., Kitakaze M. Pathophysiology of myocardial reperfusion injury: Preconditioning, postconditioning, and translational aspects of protective measures. Am. J. Physiol. Heart Circ. Physiol. 2011;301:H1723–H1741. doi: 10.1152/ajpheart.00553.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00553.2011</ArticleId><ArticleId IdType="pubmed">21856909</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Yan Y., Niu F., Wang Y., Chen X., Su G., Liu Y., Zhao X., Qian L., Liu P., et al. Ferroptosis: A cell death connecting oxidative stress, inflammation and cardiovascular diseases. Cell Death Discov. 2021;7:193. doi: 10.1038/s41420-021-00579-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-021-00579-w</ArticleId><ArticleId IdType="pmc">PMC8313570</ArticleId><ArticleId IdType="pubmed">34312370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C.P., Zhai P., Yamamoto T., Maejima Y., Matsushima S., Hariharan N., Shao D., Takagi H., Oka S., Sadoshima J. Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation. 2010;122:2170–2182. doi: 10.1161/CIRCULATIONAHA.110.958033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.110.958033</ArticleId><ArticleId IdType="pmc">PMC3003297</ArticleId><ArticleId IdType="pubmed">21060073</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C.P., Oka S., Shao D., Hariharan N., Sadoshima J. Nicotinamide phosphoribosyltransferase regulates cell survival through NAD+ synthesis in cardiac myocytes. Circ. Res. 2009;105:481–491. doi: 10.1161/CIRCRESAHA.109.203703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.109.203703</ArticleId><ArticleId IdType="pmc">PMC2765790</ArticleId><ArticleId IdType="pubmed">19661458</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari-Azad A., Hosseini L., Rajabi M., Høilund-Carlsen P.F., Vafaee M.S., Feyzizadeh S., Badalzadeh R. Nicotinamide mononucleotide and melatonin counteract myocardial ischemia-reperfusion injury by activating SIRT3/FOXO1 and reducing apoptosis in aged male rats. Mol. Biol. Rep. 2021;48:3089–3096. doi: 10.1007/s11033-021-06351-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-021-06351-8</ArticleId><ArticleId IdType="pubmed">33866495</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosseini L., Vafaee M.S., Badalzadeh R. Melatonin and Nicotinamide Mononucleotide Attenuate Myocardial Ischemia/Reperfusion Injury via Modulation of Mitochondrial Function and Hemodynamic Parameters in Aged Rats. J. Cardiovasc. Pharmacol. Ther. 2020;25:240–250. doi: 10.1177/1074248419882002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248419882002</ArticleId><ArticleId IdType="pubmed">31645107</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong D.W., Kim T.S., Cho I.T., Kim I.Y. Modification of glycolysis affects cell sensitivity to apoptosis induced by oxidative stress and mediated by mitochondria. Biochem. Biophys. Res. Commun. 2004;313:984–991. doi: 10.1016/j.bbrc.2003.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2003.12.033</ArticleId><ArticleId IdType="pubmed">14706639</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohil V.M., Sheth S.A., Nilsson R., Wojtovich A.P., Lee J.H., Perocchi F., Chen W., Clish C.B., Ayata C., Brookes P.S., et al. Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis. Nat. Biotechnol. 2010;28:249–255. doi: 10.1038/nbt.1606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1606</ArticleId><ArticleId IdType="pmc">PMC3135002</ArticleId><ArticleId IdType="pubmed">20160716</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadtochiy S.M., Urciuoli W., Zhang J., Schafer X., Munger J., Brookes P.S. Metabolomic profiling of the heart during acute ischemic preconditioning reveals a role for SIRT1 in rapid cardioprotective metabolic adaptation. J. Mol. Cell. Cardiol. 2015;88:64–72. doi: 10.1016/j.yjmcc.2015.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2015.09.008</ArticleId><ArticleId IdType="pmc">PMC4640937</ArticleId><ArticleId IdType="pubmed">26388263</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths E.J., Halestrap A.P. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Pt 1Biochem. J. 1995;307:93–98. doi: 10.1042/bj3070093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3070093</ArticleId><ArticleId IdType="pmc">PMC1136749</ArticleId><ArticleId IdType="pubmed">7717999</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M.V., Yang X.M., Downey J.M. The pH hypothesis of postconditioning: Staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation. 2007;115:1895–1903. doi: 10.1161/CIRCULATIONAHA.106.675710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.675710</ArticleId><ArticleId IdType="pubmed">17389262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadtochiy S.M., Wang Y.T., Nehrke K., Munger J., Brookes P.S. Cardioprotection by nicotinamide mononucleotide (NMN): Involvement of glycolysis and acidic pH. J. Mol. Cell. Cardiol. 2018;121:155–162. doi: 10.1016/j.yjmcc.2018.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2018.06.007</ArticleId><ArticleId IdType="pmc">PMC6103815</ArticleId><ArticleId IdType="pubmed">29958828</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamanlidis G., Lee C.F., Garcia-Menendez L., Kolwicz S.C., Jr., Suthammarak W., Gong G., Sedensky M.M., Morgan P.G., Wang W., Tian R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013;18:239–250. doi: 10.1016/j.cmet.2013.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2013.07.002</ArticleId><ArticleId IdType="pmc">PMC3779647</ArticleId><ArticleId IdType="pubmed">23931755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.F., Chavez J.D., Garcia-Menendez L., Choi Y., Roe N.D., Chiao Y.A., Edgar J.S., Goo Y.A., Goodlett D.R., Bruce J.E., et al. Normalization of NAD+ Redox Balance as a Therapy for Heart Failure. Circulation. 2016;134:883–894. doi: 10.1161/CIRCULATIONAHA.116.022495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.116.022495</ArticleId><ArticleId IdType="pmc">PMC5193133</ArticleId><ArticleId IdType="pubmed">27489254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschey M.D., Shimazu T., Goetzman E., Jing E., Schwer B., Lombard D.B., Grueter C.A., Harris C., Biddinger S., Ilkayeva O.R., et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464:121–125. doi: 10.1038/nature08778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08778</ArticleId><ArticleId IdType="pmc">PMC2841477</ArticleId><ArticleId IdType="pubmed">20203611</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J., Watanabe T. Atherosclerosis: Known and unknown. Pathol. Int. 2022;72:151–160. doi: 10.1111/pin.13202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pin.13202</ArticleId><ArticleId IdType="pubmed">35076127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasahara T., Matsushima K. Macrophage signaling, apoptosis, lectins and leukocyte trafficking. Trends Immunol. 2001;22:593–594. doi: 10.1016/S1471-4906(01)02057-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4906(01)02057-9</ArticleId><ArticleId IdType="pubmed">11698201</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara N., Kobayashi K. Macrophages in inflammation. Curr. Drug Targets. Inflamm. Allergy. 2005;4:281–286. doi: 10.2174/1568010054022024.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568010054022024</ArticleId><ArticleId IdType="pubmed">16101534</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011;31:986–1000. doi: 10.1161/ATVBAHA.110.207449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.110.207449</ArticleId><ArticleId IdType="pmc">PMC3081099</ArticleId><ArticleId IdType="pubmed">21508345</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zong Z., Zhang W., Chen Y., Wang X., Shen J., Yang C., Liu X., Deng H. Nicotinamide Mononucleotide Alleviates LPS-Induced Inflammation and Oxidative Stress via Decreasing COX-2 Expression in Macrophages. Front. Mol. Biosci. 2021;8:702107. doi: 10.3389/fmolb.2021.702107.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.702107</ArticleId><ArticleId IdType="pmc">PMC8290259</ArticleId><ArticleId IdType="pubmed">34295923</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.C., Bennett M. Aging and atherosclerosis: Mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ. Res. 2012;111:245–259. doi: 10.1161/CIRCRESAHA.111.261388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.111.261388</ArticleId><ArticleId IdType="pubmed">22773427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercken E.M., Majounie E., Ding J., Guo R., Kim J., Bernier M., Mattison J., Cookson M.R., Gorospe M., de Cabo R., et al. Age-associated miRNA alterations in skeletal muscle from rhesus monkeys reversed by caloric restriction. Aging. 2013;5:692–703. doi: 10.18632/aging.100598.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.100598</ArticleId><ArticleId IdType="pmc">PMC3808701</ArticleId><ArticleId IdType="pubmed">24036467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K., Kuwabara Y., Han J. MicroRNAs and cardiovascular diseases. FEBS J. 2011;278:1619–1633. doi: 10.1111/j.1742-4658.2011.08090.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2011.08090.x</ArticleId><ArticleId IdType="pmc">PMC3087823</ArticleId><ArticleId IdType="pubmed">21395978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss T., Giles C.B., Tarantini S., Yabluchanskiy A., Balasubramanian P., Gautam T., Csipo T., Nyúl-Tóth Á., Lipecz A., Szabo C., et al. Nicotinamide mononucleotide (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation and anti-atherogenic effects. GeroScience. 2019;41:419–439. doi: 10.1007/s11357-019-00095-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-019-00095-x</ArticleId><ArticleId IdType="pmc">PMC6815288</ArticleId><ArticleId IdType="pubmed">31463647</ArticleId></ArticleIdList></Reference><Reference><Citation>Forouzanfar M.H., Liu P., Roth G.A., Ng M., Biryukov S., Marczak L., Alexander L., Estep K., Hassen Abate K., Akinyemiju T.F., et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317:165–182. doi: 10.1001/jama.2016.19043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.19043</ArticleId><ArticleId IdType="pubmed">28097354</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L., Zhang S., Bolor-Erdene E., Wang L., Tian D., Mei Y. NAMPT/SIRT1 Attenuate Ang II-Induced Vascular Remodeling and Vulnerability to Hypertension by Inhibiting the ROS/MAPK Pathway. Oxidative Med. Cell. Longev. 2020;2020:1974265. doi: 10.1155/2020/1974265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/1974265</ArticleId><ArticleId IdType="pmc">PMC7791967</ArticleId><ArticleId IdType="pubmed">33488923</ArticleId></ArticleIdList></Reference><Reference><Citation>Huynh P.K., Wilder J., Hiller S., Hagaman J., Takahashi N., Maeda-Smithies N., Li F. Beneficial effects of nicotinamide on hypertensive mice with impaired endothelial nitric oxide function. J. Exp. Nephrol. 2020;1:1–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470241</ArticleId><ArticleId IdType="pubmed">32905409</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens C.R., Denman B.A., Mazzo M.R., Armstrong M.L., Reisdorph N., McQueen M.B., Chonchol M., Seals D.R. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat. Commun. 2018;9:1286. doi: 10.1038/s41467-018-03421-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-03421-7</ArticleId><ArticleId IdType="pmc">PMC5876407</ArticleId><ArticleId IdType="pubmed">29599478</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Sanyal S., Gao G., Gurung I.S., Zhu X., Gaconnet G., Kerchner L.J., Shang L.L., Huang C.L., Grace A., et al. Cardiac Na+ current regulation by pyridine nucleotides. Circ. Res. 2009;105:737–745. doi: 10.1161/CIRCRESAHA.109.197277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.109.197277</ArticleId><ArticleId IdType="pmc">PMC2773656</ArticleId><ArticleId IdType="pubmed">19745168</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Gu L., Sulkin M.S., Liu H., Jeong E.M., Greener I., Xie A., Efimov I.R., Dudley S.C., Jr. Mitochondrial dysfunction causing cardiac sodium channel downregulation in cardiomyopathy. J. Mol. Cell. Cardiol. 2013;54:25–34. doi: 10.1016/j.yjmcc.2012.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2012.10.011</ArticleId><ArticleId IdType="pmc">PMC3595554</ArticleId><ArticleId IdType="pubmed">23123323</ArticleId></ArticleIdList></Reference><Reference><Citation>Vikram A., Lewarchik C.M., Yoon J.Y., Naqvi A., Kumar S., Morgan G.M., Jacobs J.S., Li Q., Kim Y.R., Kassan M., et al. Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel. Nat. Med. 2017;23:361–367. doi: 10.1038/nm.4284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4284</ArticleId><ArticleId IdType="pmc">PMC6218171</ArticleId><ArticleId IdType="pubmed">28191886</ArticleId></ArticleIdList></Reference><Reference><Citation>Matasic D.S., Yoon J.Y., McLendon J.M., Mehdi H., Schmidt M.S., Greiner A.M., Quinones P., Morgan G.M., Boudreau R.L., Irani K., et al. Modulation of the cardiac sodium channel NaV1.5 peak and late currents by NAD+ precursors. J. Mol. Cell. Cardiol. 2020;141:70–81. doi: 10.1016/j.yjmcc.2020.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2020.01.013</ArticleId><ArticleId IdType="pmc">PMC7234910</ArticleId><ArticleId IdType="pubmed">32209328</ArticleId></ArticleIdList></Reference><Reference><Citation>Puccio H., Simon D., Cossée M., Criqui-Filipe P., Tiziano F., Melki J., Hindelang C., Matyas R., Rustin P., Koenig M. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 2001;27:181–186. doi: 10.1038/84818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/84818</ArticleId><ArticleId IdType="pubmed">11175786</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin A.S., Abraham D.M., Hershberger K.A., Bhatt D.P., Mao L., Cui H., Liu J., Liu X., Muehlbauer M.J., Grimsrud P.A., et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich’s ataxia cardiomyopathy model. JCI Insight. 2017;2:e93885. doi: 10.1172/jci.insight.93885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.93885</ArticleId><ArticleId IdType="pmc">PMC5518566</ArticleId><ArticleId IdType="pubmed">28724806</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield C.J., Duhamel T.A., Dhalla N.S. Mechanisms for the transition from physiological to pathological cardiac hypertrophy. Can. J. Physiol. Pharmacol. 2020;98:74–84. doi: 10.1139/cjpp-2019-0566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/cjpp-2019-0566</ArticleId><ArticleId IdType="pubmed">31815523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S., Feng J., Lin X., Liu J., Tang Y., Nie S., Gong J., Wang L. Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy. Oxidative Med. Cell. Longev. 2021;2021:5546867. doi: 10.1155/2021/5546867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5546867</ArticleId><ArticleId IdType="pmc">PMC8463245</ArticleId><ArticleId IdType="pubmed">34567409</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., Samant S., Ravindra P.V., Isbatan A., Gupta M.P. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 2010;285:3133–3144. doi: 10.1074/jbc.M109.077271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.077271</ArticleId><ArticleId IdType="pmc">PMC2823454</ArticleId><ArticleId IdType="pubmed">19940131</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamura S., Izumiya Y., Araki S., Nakamura T., Kimura Y., Hanatani S., Yamada T., Ishida T., Yamamoto M., Onoue Y., et al. Cardiomyocyte Sirt (Sirtuin) 7 Ameliorates Stress-Induced Cardiac Hypertrophy by Interacting with and Deacetylating GATA4. Hypertension. 2020;75:98–108. doi: 10.1161/HYPERTENSIONAHA.119.13357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.119.13357</ArticleId><ArticleId IdType="pubmed">31735083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Li B., Lin Q., Xu W., Zuo W., Li J., Liu N., Tu T., Zhang B., Xiao Y., et al. Nicotinamide mononucleotide attenuates isoproterenol-induced cardiac fibrosis by regulating oxidative stress and Smad3 acetylation. Life Sci. 2021;274:119299. doi: 10.1016/j.lfs.2021.119299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119299</ArticleId><ArticleId IdType="pubmed">33675899</ArticleId></ArticleIdList></Reference><Reference><Citation>Irie J., Inagaki E., Fujita M., Nakaya H., Mitsuishi M., Yamaguchi S., Yamashita K., Shigaki S., Ono T., Yukioka H., et al. Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocr. J. 2020;67:153–160. doi: 10.1507/endocrj.EJ19-0313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.EJ19-0313</ArticleId><ArticleId IdType="pubmed">31685720</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino M., Yoshino J., Kayser B.D., Patti G.J., Franczyk M.P., Mills K.F., Sindelar M., Pietka T., Patterson B.W., Imai S.I., et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372:1224–1229. doi: 10.1126/science.abe9985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe9985</ArticleId><ArticleId IdType="pmc">PMC8550608</ArticleId><ArticleId IdType="pubmed">33888596</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa-Nagahama Y., Igarashi M., Miura M., Kashiwabara K., Yaku K., Fukamizu Y., Sato T., Sakurai T., Nakagawa T., Kadowaki T., et al. Blood levels of nicotinic acid negatively correlate with hearing ability in healthy older men. BMC Geriatr. 2023;23:97. doi: 10.1186/s12877-023-03796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-023-03796-3</ArticleId><ArticleId IdType="pmc">PMC9933288</ArticleId><ArticleId IdType="pubmed">36792992</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L., Maier A.B., Tao R., Lin Z., Vaidya A., Pendse S., Thasma S., Andhalkar N., Avhad G., Kumbhar V. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45:29–43. doi: 10.1007/s11357-022-00705-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-022-00705-1</ArticleId><ArticleId IdType="pmc">PMC9735188</ArticleId><ArticleId IdType="pubmed">36482258</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng F., Zhou R., Lin C., Yang S., Wang H., Li W., Zheng K., Lin W., Li X., Yao X., et al. Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer. Theranostics. 2019;9:1001–1014. doi: 10.7150/thno.30056.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.30056</ArticleId><ArticleId IdType="pmc">PMC6401398</ArticleId><ArticleId IdType="pubmed">30867812</ArticleId></ArticleIdList></Reference><Reference><Citation>Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34:360–394. doi: 10.1101/gad.334516.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.334516.119</ArticleId><ArticleId IdType="pmc">PMC7050487</ArticleId><ArticleId IdType="pubmed">32029455</ArticleId></ArticleIdList></Reference><Reference><Citation>Garten A., Grohmann T., Kluckova K., Lavery G.G., Kiess W., Penke M. Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1. Int. J. Mol. Sci. 2019;20:4048. doi: 10.3390/ijms20164048.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20164048</ArticleId><ArticleId IdType="pmc">PMC6719220</ArticleId><ArticleId IdType="pubmed">31430957</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson A.E., Yeung C., Issaq S.H., Collins V.J., Gouzoulis M., Zhang Y., Ji J., Mendoza A., Heske C.M. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma. Oncogenesis. 2020;9:80. doi: 10.1038/s41389-020-00264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41389-020-00264-0</ArticleId><ArticleId IdType="pmc">PMC7481307</ArticleId><ArticleId IdType="pubmed">32908120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma R., Wu Y., Zhai Y., Hu B., Ma W., Yang W., Yu Q., Chen Z., Workman J.L., Yu X., et al. Exogenous pyruvate represses histone gene expression and inhibits cancer cell proliferation via the NAMPT-NAD+-SIRT1 pathway. Nucleic Acids Res. 2019;47:11132–11150. doi: 10.1093/nar/gkz864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz864</ArticleId><ArticleId IdType="pmc">PMC6868375</ArticleId><ArticleId IdType="pubmed">31598701</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>